Editas Medicine, Inc. (0IFK.L)
0IFK.L Stock Price Chart
Explore Editas Medicine, Inc. interactive price chart. Choose custom timeframes to analyze 0IFK.L price movements and trends.
0IFK.L Company Profile
Discover essential business fundamentals and corporate details for Editas Medicine, Inc. (0IFK.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
246.00
Website
https://www.editasmedicine.comCEO
Gilmore O'Neill
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
0IFK.L Financial Timeline
Browse a chronological timeline of Editas Medicine, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 3 Mar 2026
Upcoming earnings on 3 Nov 2025
Upcoming earnings on 5 Aug 2025
Revenue estimate is $1.80M.
Earnings released on 12 May 2025
EPS came in at -$0.92 falling short of the estimated -$0.56 by -63.13%, while revenue for the quarter reached $4.66M, beating expectations by +559.68%.
Earnings released on 5 Mar 2025
EPS came in at -$0.55 falling short of the estimated -$0.38 by -45.61%, while revenue for the quarter reached $30.60M, beating expectations by +4.68K%.
Earnings released on 4 Nov 2024
EPS came in at -$0.75 falling short of the estimated -$0.75 by -0.85%, while revenue for the quarter reached $61.00K, missing expectations by -98.45%.
Earnings released on 7 Aug 2024
EPS came in at -$0.82 falling short of the estimated -$0.70 by -16.67%, while revenue for the quarter reached $513.00K, missing expectations by -89.27%.
Earnings released on 8 May 2024
EPS came in at -$0.76 falling short of the estimated -$0.63 by -20.86%, while revenue for the quarter reached $1.14M, missing expectations by -89.81%.
Earnings released on 4 Mar 2024
EPS came in at -$0.23 surpassing the estimated -$0.59 by +61.11%, while revenue for the quarter reached $60.05M, beating expectations by +1.52K%.
Earnings released on 3 Nov 2023
EPS came in at -$0.55 surpassing the estimated -$0.58 by +4.12%, while revenue for the quarter reached $5.34M, beating expectations by +44.08%.
Earnings released on 2 Aug 2023
EPS came in at -$0.56 surpassing the estimated -$0.77 by +26.39%, while revenue for the quarter reached $2.89M, missing expectations by -30.80%.
Earnings released on 5 May 2023
EPS came in at -$0.71 surpassing the estimated -$0.78 by +9.26%, while revenue for the quarter reached $9.85M, beating expectations by +199.87%.
Earnings released on 22 Feb 2023
EPS came in at -$0.88 falling short of the estimated -$0.79 by -11.96%, while revenue for the quarter reached $6.54M, beating expectations by +78.68%.
Earnings released on 30 Sept 2022
EPS came in at -$0.81 surpassing the estimated -$0.85 by +4.95%, while revenue for the quarter reached $42.00K, missing expectations by -99.04%.
Earnings released on 30 Jun 2022
EPS came in at -$0.78 surpassing the estimated -$0.81 by +3.66%, while revenue for the quarter reached $6.36M, beating expectations by +48.28%.
Earnings released on 31 Mar 2022
EPS came in at -$0.74 surpassing the estimated -$0.78 by +5.64%, while revenue for the quarter reached $6.77M, beating expectations by +75.76%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 23 Feb 2022
EPS came in at -$0.61 surpassing the estimated -$0.71 by +14.88%, while revenue for the quarter reached $12.47M, beating expectations by +168.51%.
Earnings released on 8 Nov 2021
EPS came in at -$0.81, while revenue for the quarter reached $379.00K.
Earnings released on 30 Sept 2021
EPS came in at -$0.57, while revenue for the quarter reached $6.20M.
Earnings released on 31 Mar 2021
EPS came in at -$0.86, while revenue for the quarter reached $6.50M.
Earnings released on 31 Dec 2020
EPS came in at -$1.00, while revenue for the quarter reached $11.42M.
Earnings released on 30 Sept 2020
EPS came in at $0.12, while revenue for the quarter reached $62.84M.
0IFK.L Stock Performance
Access detailed 0IFK.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.